HRP20171150T1 - Novi spojevi - Google Patents
Novi spojevi Download PDFInfo
- Publication number
- HRP20171150T1 HRP20171150T1 HRP20171150TT HRP20171150T HRP20171150T1 HR P20171150 T1 HRP20171150 T1 HR P20171150T1 HR P20171150T T HRP20171150T T HR P20171150TT HR P20171150 T HRP20171150 T HR P20171150T HR P20171150 T1 HRP20171150 T1 HR P20171150T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrrolo
- pyrimidin
- amine
- butyl
- pentyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 24
- 150000003839 salts Chemical class 0.000 claims 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- TZLSTRPCSHSSJJ-UHFFFAOYSA-N 2-butyl-6-methyl-7-(6-pyrrolidin-1-ylhexyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCCCN1CCCC1 TZLSTRPCSHSSJJ-UHFFFAOYSA-N 0.000 claims 2
- JNSVNACCUJRHFR-UHFFFAOYSA-N 2-butyl-7-(5-pyrrolidin-1-ylpentyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CCCC1 JNSVNACCUJRHFR-UHFFFAOYSA-N 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052731 fluorine Chemical group 0.000 claims 2
- 239000011737 fluorine Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- ONLBRQXZJKHCHO-HNNXBMFYSA-N (3s)-1-[5-(4-amino-2-butyl-5h-pyrrolo[3,2-d]pyrimidin-7-yl)pentyl]pyrrolidin-3-ol Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CC[C@H](O)C1 ONLBRQXZJKHCHO-HNNXBMFYSA-N 0.000 claims 1
- UJKLLMLXDMSHGM-UHFFFAOYSA-N 1-[5-(4-amino-2-butyl-5h-pyrrolo[3,2-d]pyrimidin-7-yl)pentyl]azetidin-3-ol Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CC(O)C1 UJKLLMLXDMSHGM-UHFFFAOYSA-N 0.000 claims 1
- NUIFYBSFJSWRDC-UHFFFAOYSA-N 1-[5-(4-amino-2-butyl-5h-pyrrolo[3,2-d]pyrimidin-7-yl)pentyl]piperidin-4-ol Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CCC(O)CC1 NUIFYBSFJSWRDC-UHFFFAOYSA-N 0.000 claims 1
- QOVXBXDUTWRRLZ-UHFFFAOYSA-N 2-(2-methoxyethyl)-7-(5-pyrrolidin-1-ylpentyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCOC)=NC(N)=C2NC=C1CCCCCN1CCCC1 QOVXBXDUTWRRLZ-UHFFFAOYSA-N 0.000 claims 1
- CJPDSDQTCRHROJ-UHFFFAOYSA-N 2-(2-methoxyethyl)-7-(6-piperidin-1-ylhexyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCOC)=NC(N)=C2NC=C1CCCCCCN1CCCCC1 CJPDSDQTCRHROJ-UHFFFAOYSA-N 0.000 claims 1
- NRKGRVDVTLKHEK-UHFFFAOYSA-N 2-(ethoxymethyl)-7-(6-piperidin-1-ylhexyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(COCC)=NC(N)=C2NC=C1CCCCCCN1CCCCC1 NRKGRVDVTLKHEK-UHFFFAOYSA-N 0.000 claims 1
- YDSBKNJZTMGORA-UHFFFAOYSA-N 2-butyl-6-methyl-7-(4-piperidin-1-ylbutyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCN1CCCCC1 YDSBKNJZTMGORA-UHFFFAOYSA-N 0.000 claims 1
- JFRRKMLRRBYRII-UHFFFAOYSA-N 2-butyl-6-methyl-7-(4-pyrrolidin-1-ylbutyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCN1CCCC1 JFRRKMLRRBYRII-UHFFFAOYSA-N 0.000 claims 1
- BBYYXIYMTHQBAN-UHFFFAOYSA-N 2-butyl-6-methyl-7-(5-piperidin-1-ylpentyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCCN1CCCCC1 BBYYXIYMTHQBAN-UHFFFAOYSA-N 0.000 claims 1
- XJXYEBAKTVNASV-UHFFFAOYSA-N 2-butyl-6-methyl-7-(5-pyrrolidin-1-ylpentyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCCN1CCCC1 XJXYEBAKTVNASV-UHFFFAOYSA-N 0.000 claims 1
- HVPPYXLDUJABGI-UHFFFAOYSA-N 2-butyl-6-methyl-7-(6-piperidin-1-ylhexyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCCCN1CCCCC1 HVPPYXLDUJABGI-UHFFFAOYSA-N 0.000 claims 1
- KOIZLYAOQNLWEG-UHFFFAOYSA-N 2-butyl-7-(4-piperidin-1-ylbutyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCN1CCCCC1 KOIZLYAOQNLWEG-UHFFFAOYSA-N 0.000 claims 1
- XUSRJGRTPVPVMS-UHFFFAOYSA-N 2-butyl-7-(5-piperidin-1-ylpentyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CCCCC1 XUSRJGRTPVPVMS-UHFFFAOYSA-N 0.000 claims 1
- BXNDDJRFAGNGMK-UHFFFAOYSA-N 2-butyl-7-(6-piperidin-1-ylhexyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCCN1CCCCC1 BXNDDJRFAGNGMK-UHFFFAOYSA-N 0.000 claims 1
- HGKIESKSVLFTCX-UHFFFAOYSA-N 2-butyl-7-(6-pyrrolidin-1-ylhexyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCCN1CCCC1 HGKIESKSVLFTCX-UHFFFAOYSA-N 0.000 claims 1
- GIZMIPUBWIVEMY-UHFFFAOYSA-N 2-butyl-7-[5-(3-fluoroazetidin-1-yl)pentyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CC(F)C1 GIZMIPUBWIVEMY-UHFFFAOYSA-N 0.000 claims 1
- PLCQDPIZUBFPME-UHFFFAOYSA-N 2-butyl-7-[5-(3-fluoroazetidin-1-yl)pentyl]-6-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCCN1CC(F)C1 PLCQDPIZUBFPME-UHFFFAOYSA-N 0.000 claims 1
- LOJMQSDMWAEWIU-UHFFFAOYSA-N 2-butyl-7-[5-(3-methylazetidin-1-yl)pentyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CC(C)C1 LOJMQSDMWAEWIU-UHFFFAOYSA-N 0.000 claims 1
- GKPSHVSZVUHZAE-UHFFFAOYSA-N 2-butyl-7-[5-(4,4-difluoropiperidin-1-yl)pentyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CCC(F)(F)CC1 GKPSHVSZVUHZAE-UHFFFAOYSA-N 0.000 claims 1
- UXXCZVQDTUOKDS-UHFFFAOYSA-N 2-butyl-7-[5-(4-fluoropiperidin-1-yl)pentyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CCC(F)CC1 UXXCZVQDTUOKDS-UHFFFAOYSA-N 0.000 claims 1
- DMJIEKOQMGIOJP-UHFFFAOYSA-N 2-butyl-7-[5-(4-fluoropiperidin-1-yl)pentyl]-6-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCCN1CCC(F)CC1 DMJIEKOQMGIOJP-UHFFFAOYSA-N 0.000 claims 1
- PDYLKPZLDUGILJ-OAHLLOKOSA-N 2-butyl-7-[5-[(2r)-2-methylpyrrolidin-1-yl]pentyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CCC[C@H]1C PDYLKPZLDUGILJ-OAHLLOKOSA-N 0.000 claims 1
- PDYLKPZLDUGILJ-HNNXBMFYSA-N 2-butyl-7-[5-[(2s)-2-methylpyrrolidin-1-yl]pentyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CCC[C@@H]1C PDYLKPZLDUGILJ-HNNXBMFYSA-N 0.000 claims 1
- DFCDHUHEVOQGMB-OAHLLOKOSA-N 2-butyl-7-[5-[(3r)-3-fluoropyrrolidin-1-yl]pentyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CC[C@@H](F)C1 DFCDHUHEVOQGMB-OAHLLOKOSA-N 0.000 claims 1
- KRSBEXDSLZJPCB-OAHLLOKOSA-N 2-butyl-7-[5-[(3r)-3-fluoropyrrolidin-1-yl]pentyl]-6-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCCN1CC[C@@H](F)C1 KRSBEXDSLZJPCB-OAHLLOKOSA-N 0.000 claims 1
- DFCDHUHEVOQGMB-HNNXBMFYSA-N 2-butyl-7-[5-[(3s)-3-fluoropyrrolidin-1-yl]pentyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CC[C@H](F)C1 DFCDHUHEVOQGMB-HNNXBMFYSA-N 0.000 claims 1
- KRSBEXDSLZJPCB-HNNXBMFYSA-N 2-butyl-7-[5-[(3s)-3-fluoropyrrolidin-1-yl]pentyl]-6-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCCN1CC[C@H](F)C1 KRSBEXDSLZJPCB-HNNXBMFYSA-N 0.000 claims 1
- DVZMVHKJRALNNZ-UHFFFAOYSA-N 2-butyl-7-[6-(4-fluoropiperidin-1-yl)hexyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCCN1CCC(F)CC1 DVZMVHKJRALNNZ-UHFFFAOYSA-N 0.000 claims 1
- ZYYVJTHLNWJMGI-MRXNPFEDSA-N 2-butyl-7-[6-[(3r)-3-fluoropyrrolidin-1-yl]hexyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCCN1CC[C@@H](F)C1 ZYYVJTHLNWJMGI-MRXNPFEDSA-N 0.000 claims 1
- ZYYVJTHLNWJMGI-INIZCTEOSA-N 2-butyl-7-[6-[(3s)-3-fluoropyrrolidin-1-yl]hexyl]-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCCN1CC[C@H](F)C1 ZYYVJTHLNWJMGI-INIZCTEOSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- HQAGHNHNCDXPNX-UHFFFAOYSA-N 2-pentyl-7-(6-piperidin-1-ylhexyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCCC)=NC(N)=C2NC=C1CCCCCCN1CCCCC1 HQAGHNHNCDXPNX-UHFFFAOYSA-N 0.000 claims 1
- BMCHFRSACPPETD-UHFFFAOYSA-N 7-[4-(azepan-1-yl)butyl]-2-butyl-6-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCN1CCCCCC1 BMCHFRSACPPETD-UHFFFAOYSA-N 0.000 claims 1
- YLVPWHVYQCDVEH-UHFFFAOYSA-N 7-[5-(4-fluoropiperidin-1-yl)pentyl]-2-(2-methoxyethyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCOC)=NC(N)=C2NC=C1CCCCCN1CCC(F)CC1 YLVPWHVYQCDVEH-UHFFFAOYSA-N 0.000 claims 1
- RDJYOQQEFXXBOS-UHFFFAOYSA-N 7-[5-(azepan-1-yl)pentyl]-2-butyl-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CCCCCC1 RDJYOQQEFXXBOS-UHFFFAOYSA-N 0.000 claims 1
- SSONSLOIXPFRKK-UHFFFAOYSA-N 7-[5-(azetidin-1-yl)pentyl]-2-butyl-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CCC1 SSONSLOIXPFRKK-UHFFFAOYSA-N 0.000 claims 1
- DBRAROMRCAHKED-UHFFFAOYSA-N 7-[5-(azetidin-1-yl)pentyl]-2-butyl-6-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCCN1CCC1 DBRAROMRCAHKED-UHFFFAOYSA-N 0.000 claims 1
- HQQDWWKPOBOUTN-CQSZACIVSA-N 7-[5-[(3r)-3-fluoropyrrolidin-1-yl]pentyl]-2-(2-methoxyethyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCOC)=NC(N)=C2NC=C1CCCCCN1CC[C@@H](F)C1 HQQDWWKPOBOUTN-CQSZACIVSA-N 0.000 claims 1
- HQQDWWKPOBOUTN-AWEZNQCLSA-N 7-[5-[(3s)-3-fluoropyrrolidin-1-yl]pentyl]-2-(2-methoxyethyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCOC)=NC(N)=C2NC=C1CCCCCN1CC[C@H](F)C1 HQQDWWKPOBOUTN-AWEZNQCLSA-N 0.000 claims 1
- KMOKGGFYQWSCBS-UHFFFAOYSA-N 7-[6-(azepan-1-yl)hexyl]-2-(2-methoxyethyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCOC)=NC(N)=C2NC=C1CCCCCCN1CCCCCC1 KMOKGGFYQWSCBS-UHFFFAOYSA-N 0.000 claims 1
- QWPFKANQWPPUBP-UHFFFAOYSA-N 7-[6-(azetidin-1-yl)hexyl]-2-butyl-6-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC(C)=C1CCCCCCN1CCC1 QWPFKANQWPPUBP-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (22)
1. Spoj formule (I), ili njegova sol:
[image]
,
naznačen time što:
R1 je n-C4-6alkil ili C1-2alkoksiC1-2alkil-;
R2 je vodik ili metil;
svaki R3 je hidroksi, halogen ili n-C1-3alkil;
m je cijeli broj, s vrijednošću od 2 to 4;
n je cijeli broj, s vrijednošću od 0 do 3;
p je cijeli broj, s vrijednošću od 0 do 2.
2. Spoj u skladu s patentnim zahtjevom 1, ili njegova sol, naznačen time što R1 je n-butil.
3. Spoj u skladu s patentnim zahtjevom 1, ili njegova sol, naznačen time što R1 je etoksimetil.
4. Spoj u skladu s patentnim zahtjevom 1, ili njegova sol, naznačen time što R1 je 2-metoksietil.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-4, ili njegova sol, naznačen time što je R2 vodik.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-4, ili njegova sol, naznačen time što je R2 metil.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-6, ili njegova sol, naznačen time što je n cijeli broj, s vrijednošću od 1 ili 2.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-7, ili njegova sol, naznačen time što je p 0.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-7, ili njegova sol, naznačen time što R3 je hidroksi ili halogen.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-7, ili njegova sol, naznačen time što je p 1, a R3 je hidroksi ili fluor.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-7, ili njegova sol, naznačen time što je p 2, a R3 je fluor.
12. Spoj u skladu s patentnim zahtjevom 1, ili njegova sol, naznačen time što se bira iz skupine koju čine:
2-butil-7-(6-(piperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(5-(piperidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(4-(piperidin-1-il)butil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-(etoksimetil)-7-(6-(piperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-(2-metoksietil)-7-(6-(piperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-6-metil-7-(6-(piperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-6-metil-7-(5-(piperidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-6-metil-7-(4-(piperidin-1-il)butil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(5-(pirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(6-(pirolidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-pentil-7-(6-(piperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
7-(5-(azepan-1-il)pentil)-2-butil-5H-pirolo[3,2-d]pirimidin-4-amin;
7-(4-(azepan-1-il)butil)-2-butil-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-6-metil-7-(6-(pirolidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
7-(6-(azetidin-1-il)heksil)-2-butil-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-6-metil-7-(5-(pirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
7-(5-(azetidin-1-il)pentil)-2-butil-5H-pirolo[3,2-d]pirimidin-4-amin;
7-(5-(azetidin-1-il)pentil)-2-butil-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-6-metil-7-(4-(pirolidin-1-il)butil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(5-(4,4-difluorpiperidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(5-(4-fluorpiperidin-l-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
7-(5-(4-fluorpiperidin-1-il)pentil)-2-(2-metoksietil)-5H-pirolo[3,2-d]pirimidin-4-amin;
1-(5-(4-amino-2-butil-5H-pirolo[3,2-d]pirimidin-7-il)pentil)piperidin-4-ol;
(R)-2-butil-7-(5-(3-fluorpirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
(S)-2-butil-7-(5-(3-fluorpirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
(R)-7-(5-(3-fluorpirolidin-1-il)pentil)-2-(2-metoksietil)-5H-pirolo[3,2-d]pirimidin-4-amin;
(S)-7-(5-(3-fluorpirolidin-1-il)pentil)-2-(2-metoksietil)-5H-pirolo[3,2-d]pirimidin-4-amin;
(S)-1-(5-(4-amino-2-butil-5H-pirolo[3,2-d]pirimidin-7-il)pentil)pirolidin-3-ol;
1-(5-(4-amino-2-butil-5H-pirolo[3,2-d]pirimidin-7-il)pentil)azetidin-3-ol;
7-(6-(azepan-1-il)heksil)-2-(2-metoksietil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(6-(4-fluorpiperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
(R)-2-butil-7-(6-(3-fluorpirolidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
(S)-2-butil-7-(6-(3-fluorpirolidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
(S)-2-butil-7-(5-(2-metilpirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
(R)-2-butil-7-(5-(2-metilpirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(5-(3-metilazetidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(5-(3-fluorazetidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-6-metil-7-(6-(pirolidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(5-(4-fluorpiperidin-1-il)pentil)-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin;
(S)-2-butil-7-(5-(3-fluorpirolidin-1-il)pentil)-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin;
(R)-2-butil-7-(5-(3-fluorpirolidin-1-il)pentil)-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin;
2-butil-7-(5-(3-fluorazetidin-1-il)pentil)-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin; i
2-(2-metoksietil)-7-(5-(pirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin.
13. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 2-butil-7-(5-(pirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin
[image]
,
ili njegova sol.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što je u obliku farmaceutski prihvatljive soli.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što je u obliku slobodne baze.
16. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-13, ili njegovu farmaceutski prihvatljivu sol, kao i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
17. Cjepivni pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-13, ili njegovu farmaceutski prihvatljivu sol, kao i antigen ili antigenski pripravak.
18. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-13, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
19. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-13, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju alergijskih bolesti i drugih upalnih stanja, zaraznih bolesti i raka.
20. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-13, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju alergijskog rinitisa.
21. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-13, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju astme.
22. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1-13, ili njegove farmaceutski prihvatljive soli, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje alergijskih bolesti i drugih upalnih stanja, zaraznih bolesti i raka.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261728390P | 2012-11-20 | 2012-11-20 | |
US201361774087P | 2013-03-07 | 2013-03-07 | |
PCT/US2013/070472 WO2014081645A1 (en) | 2012-11-20 | 2013-11-18 | Novel compounds |
EP13857477.7A EP2922549B1 (en) | 2012-11-20 | 2013-11-18 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171150T1 true HRP20171150T1 (hr) | 2017-10-06 |
Family
ID=50776485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171150TT HRP20171150T1 (hr) | 2012-11-20 | 2017-07-27 | Novi spojevi |
Country Status (32)
Country | Link |
---|---|
US (3) | US9540383B2 (hr) |
EP (1) | EP2922549B1 (hr) |
JP (1) | JP6228223B2 (hr) |
KR (1) | KR20150085055A (hr) |
CN (1) | CN104780922B (hr) |
AU (1) | AU2013348218B2 (hr) |
BR (1) | BR112015011400A8 (hr) |
CA (1) | CA2892218A1 (hr) |
CL (1) | CL2015001342A1 (hr) |
CR (1) | CR20150268A (hr) |
CY (1) | CY1119557T1 (hr) |
DK (1) | DK2922549T3 (hr) |
DO (1) | DOP2015000121A (hr) |
EA (1) | EA028480B1 (hr) |
ES (1) | ES2639789T3 (hr) |
HK (1) | HK1208826A1 (hr) |
HR (1) | HRP20171150T1 (hr) |
HU (1) | HUE13857477T2 (hr) |
IL (1) | IL238800B (hr) |
LT (1) | LT2922549T (hr) |
ME (1) | ME02867B (hr) |
MX (1) | MX358025B (hr) |
NZ (1) | NZ707319A (hr) |
PE (1) | PE20151086A1 (hr) |
PH (1) | PH12015501100B1 (hr) |
PL (1) | PL2922549T3 (hr) |
PT (1) | PT2922549T (hr) |
RS (1) | RS56233B1 (hr) |
SG (1) | SG11201503282RA (hr) |
SI (1) | SI2922549T1 (hr) |
UA (1) | UA114645C2 (hr) |
WO (1) | WO2014081645A1 (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
WO2013014052A1 (en) | 2011-07-22 | 2013-01-31 | Glaxosmithkline Llc | Composition |
EP2888264B1 (en) | 2012-08-24 | 2017-09-27 | Glaxosmithkline LLC | Pyrazolopyrimidine compounds |
BR112015011439A2 (pt) | 2012-11-20 | 2017-07-11 | Glaxosmithkline Llc | composto, composição farmacêutica, composição de vacina, e, uso de um composto |
ES2632448T3 (es) | 2012-11-20 | 2017-09-13 | Glaxosmithkline Llc | Nuevos compuestos |
HUE13857477T2 (hu) | 2012-11-20 | 2018-05-28 | Glaxosmithkline Llc | Új vegyületek |
CA2938476A1 (en) * | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon |
PL3190113T3 (pl) * | 2014-08-15 | 2021-10-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Związki pirolopirymidynowe stosowane jako agonista TLR7 |
CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
TWI558709B (zh) * | 2015-10-07 | 2016-11-21 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Pyrrolopyrimidine ring compounds, their use and pharmaceutical compositions |
CN108349982B (zh) * | 2015-11-05 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的7-(噻唑-5-基)吡咯并嘧啶化合物 |
CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
US7125880B1 (en) | 1995-06-06 | 2006-10-24 | Pfizer Inc. | Corticotropin releasing factor antagonists |
AU3176297A (en) * | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
US5985848A (en) * | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
IL150594A0 (en) | 2000-01-07 | 2003-02-12 | Ustav Ex Botan Adademie Ved Ce | Purine derivatives, process for their preparation and use |
CN101016296A (zh) | 2000-04-28 | 2007-08-15 | 阿卡蒂亚药品公司 | 毒蕈碱性激动剂 |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
TW200301251A (en) | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
ATE478872T1 (de) | 2002-03-28 | 2010-09-15 | Ustav Ex Botan Av Cr V V I I O | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung |
KR20050006221A (ko) * | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
US6713241B2 (en) | 2002-08-09 | 2004-03-30 | Eastman Kodak Company | Thermally developable emulsions and imaging materials containing binder mixture |
US7553839B2 (en) | 2002-08-21 | 2009-06-30 | Industrial Research Limited | 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
AU2003271064B2 (en) | 2002-09-27 | 2010-06-17 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound and use thereof |
CN1816530A (zh) | 2003-07-01 | 2006-08-09 | 麦克公司 | 用于治疗高眼压症的眼用组合物 |
US20070161582A1 (en) | 2003-08-08 | 2007-07-12 | Dusan Mijikovic | Pharmaceutical compositions and methods for metabolic modulation |
ES2342069T4 (es) | 2003-09-05 | 2011-01-26 | Anadys Pharmaceuticals, Inc. | Ligandos de tlr7 para el tratamiento de la hepatitis c. |
UY28506A1 (es) | 2003-09-12 | 2005-04-29 | Basf Ag | 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales. |
KR101494056B1 (ko) | 2003-10-03 | 2015-02-16 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피라졸로피리딘 및 그의 유사체 |
WO2005092892A1 (ja) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8−オキソアデニン化合物 |
CA2559036C (en) | 2004-03-26 | 2013-08-20 | Dainippon Sumitomo Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
TWI378934B (en) | 2004-04-02 | 2012-12-11 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
MXPA06013250A (es) | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
JP2008540396A (ja) | 2005-05-04 | 2008-11-20 | ファイザー・リミテッド | 癌およびc型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての2−アミド−6−アミノ−8−オキソプリン誘導体 |
NZ540160A (en) * | 2005-05-20 | 2008-03-28 | Einstein Coll Med | Inhibitors of nucleoside phosphorylases |
JP2009502801A (ja) | 2005-07-22 | 2009-01-29 | サネシス ファーマシューティカルズ, インコーポレイテッド | Auroraキナーゼインヒビターとして有用なピラゾロピリミジン |
WO2007024707A2 (en) | 2005-08-22 | 2007-03-01 | The Regents Of The University Of California | Tlr agonists |
RU2008110908A (ru) | 2005-08-25 | 2009-09-27 | Шеринг Корпорейшн (US) | Производные имидазола в качестве функционально селективных агонистов альфа2с адренорецепторов |
US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
AU2006287157A1 (en) | 2005-09-02 | 2007-03-08 | Pfizer Inc. | Hydroxy substituted 1H-imidazopyridines and methods |
TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
JPWO2007034817A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
JPWO2007034881A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
EP1939200A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
EP1939199A4 (en) | 2005-09-22 | 2010-10-20 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
EP1939201A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
ES2374455T3 (es) | 2006-02-17 | 2012-02-16 | Pfizer Limited | Derivados de 3-deazapurinza como moduladores de tlr7. |
CA2680789C (en) | 2006-03-28 | 2016-02-16 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
EP2029597A4 (en) | 2006-05-31 | 2011-11-23 | Univ California | purine analogs |
GB2438679A (en) | 2006-05-31 | 2007-12-05 | Sra Dev Ltd | Ultrasonic surgical tool having two modes of vibration |
JP2009542645A (ja) | 2006-07-05 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | Tlr7のモジュレーターとして作用する8−オキソアデニン誘導体 |
PL2038290T3 (pl) | 2006-07-07 | 2014-03-31 | Gilead Sciences Inc | Modulatory receptora Toll-podobnego 7 |
CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
TW200831105A (en) | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
DK2125792T3 (da) | 2007-02-19 | 2011-03-07 | Glaxosmithkline Llc | Purinderivater som immunomodulatorer |
EP2132209B8 (en) | 2007-03-19 | 2014-04-16 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators |
ES2373616T3 (es) | 2007-03-19 | 2012-02-07 | Astrazeneca Ab | Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7). |
EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
PE20081887A1 (es) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
CN101784548B (zh) | 2007-06-29 | 2013-07-17 | 吉里德科学公司 | 嘌呤衍生物及其作为toll样受体7的调节剂的用途 |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
CN101842098A (zh) | 2007-08-10 | 2010-09-22 | 基因实验室技术有限公司 | 用于治疗病毒感染的含氮的二环化学实体 |
UY31531A1 (es) | 2007-12-17 | 2009-08-03 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
ITMO20080210A1 (it) | 2008-08-01 | 2010-02-02 | Marco Seghedoni | Veicolo per il sollevamento e la movimentazione di manufatti |
US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
BRPI0917013A2 (pt) | 2008-08-11 | 2016-02-16 | Glaxosmithkline Llc | métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto |
EP2324025A1 (en) | 2008-08-11 | 2011-05-25 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
WO2010018132A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Compounds |
EP2326646B1 (en) | 2008-08-11 | 2013-07-31 | GlaxoSmithKline LLC | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
CN102548999A (zh) | 2009-01-20 | 2012-07-04 | 山东轩竹医药科技有限公司 | 含有取代的含氮稠杂环的头孢菌素衍生物 |
JP5861243B2 (ja) * | 2009-07-17 | 2016-02-16 | アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ | 5’−メチルチオアデノシンホスホリラーゼ及びヌクレオシダーゼの3−ヒドロキシピロリジン阻害剤 |
EA023536B1 (ru) | 2009-08-07 | 2016-06-30 | Глаксосмитклайн Байолоджикалс Са | Производные оксоаденина, конъюгированные с фосфо- или фосфонолипидами |
JP2013519644A (ja) | 2010-02-10 | 2013-05-30 | グラクソスミスクライン エルエルシー | プリン誘導体およびそれらの薬学的使用 |
US8703754B2 (en) | 2010-02-10 | 2014-04-22 | Glaxosmithkline Llc | 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
AU2012212323A1 (en) | 2011-02-01 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
EP2670244B1 (en) | 2011-02-04 | 2018-04-11 | Duquesne University of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
CA2837207A1 (en) * | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
WO2013014052A1 (en) | 2011-07-22 | 2013-01-31 | Glaxosmithkline Llc | Composition |
EP2888264B1 (en) | 2012-08-24 | 2017-09-27 | Glaxosmithkline LLC | Pyrazolopyrimidine compounds |
BR112015011439A2 (pt) | 2012-11-20 | 2017-07-11 | Glaxosmithkline Llc | composto, composição farmacêutica, composição de vacina, e, uso de um composto |
ES2632448T3 (es) | 2012-11-20 | 2017-09-13 | Glaxosmithkline Llc | Nuevos compuestos |
HUE13857477T2 (hu) | 2012-11-20 | 2018-05-28 | Glaxosmithkline Llc | Új vegyületek |
CA2938476A1 (en) | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon |
-
2013
- 2013-11-18 HU HUE13857477A patent/HUE13857477T2/hu unknown
- 2013-11-18 PT PT138574777T patent/PT2922549T/pt unknown
- 2013-11-18 SI SI201330751T patent/SI2922549T1/sl unknown
- 2013-11-18 PL PL13857477T patent/PL2922549T3/pl unknown
- 2013-11-18 SG SG11201503282RA patent/SG11201503282RA/en unknown
- 2013-11-18 KR KR1020157015893A patent/KR20150085055A/ko not_active Application Discontinuation
- 2013-11-18 EA EA201590684A patent/EA028480B1/ru not_active IP Right Cessation
- 2013-11-18 NZ NZ70731913A patent/NZ707319A/en unknown
- 2013-11-18 ES ES13857477.7T patent/ES2639789T3/es active Active
- 2013-11-18 JP JP2015542860A patent/JP6228223B2/ja not_active Expired - Fee Related
- 2013-11-18 BR BR112015011400A patent/BR112015011400A8/pt not_active Application Discontinuation
- 2013-11-18 EP EP13857477.7A patent/EP2922549B1/en active Active
- 2013-11-18 US US14/443,932 patent/US9540383B2/en active Active
- 2013-11-18 AU AU2013348218A patent/AU2013348218B2/en not_active Ceased
- 2013-11-18 CA CA2892218A patent/CA2892218A1/en not_active Abandoned
- 2013-11-18 UA UAA201504354A patent/UA114645C2/uk unknown
- 2013-11-18 LT LTEP13857477.7T patent/LT2922549T/lt unknown
- 2013-11-18 RS RS20170841A patent/RS56233B1/sr unknown
- 2013-11-18 ME MEP-2017-188A patent/ME02867B/me unknown
- 2013-11-18 MX MX2015006375A patent/MX358025B/es active IP Right Grant
- 2013-11-18 WO PCT/US2013/070472 patent/WO2014081645A1/en active Application Filing
- 2013-11-18 PE PE2015000637A patent/PE20151086A1/es active IP Right Grant
- 2013-11-18 DK DK13857477.7T patent/DK2922549T3/en active
- 2013-11-18 CN CN201380060067.8A patent/CN104780922B/zh not_active Expired - Fee Related
-
2015
- 2015-05-13 IL IL238800A patent/IL238800B/en not_active IP Right Cessation
- 2015-05-18 CL CL2015001342A patent/CL2015001342A1/es unknown
- 2015-05-18 PH PH12015501100A patent/PH12015501100B1/en unknown
- 2015-05-20 DO DO2015000121A patent/DOP2015000121A/es unknown
- 2015-05-20 CR CR20150268A patent/CR20150268A/es unknown
- 2015-09-30 HK HK15109639.1A patent/HK1208826A1/xx not_active IP Right Cessation
-
2016
- 2016-12-06 US US15/370,211 patent/US9907847B2/en active Active
-
2017
- 2017-07-27 HR HRP20171150TT patent/HRP20171150T1/hr unknown
- 2017-08-24 CY CY20171100898T patent/CY1119557T1/el unknown
-
2018
- 2018-01-18 US US15/873,996 patent/US20180140695A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171150T1 (hr) | Novi spojevi | |
HRP20180202T1 (hr) | Purinski derivati, namijenjeni upotrebi u liječenju alergijskih, upalnih i zaraznih bolesti | |
RU2015117251A (ru) | Новые соединения | |
ZA202303227B (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
NI201400151A (es) | 7H - PIRROLO [ 2, 3 - d ] PIRIMIDINAS 4 - ( AMINO - SUBSTITUIDAS ) NOVEDOSAS COMO INHIBIDORES DE LRRK2. | |
JP2014522855A5 (hr) | ||
JP2016500068A5 (hr) | ||
IN2014MN01754A (hr) | ||
NZ702063A (en) | Compositions comprising short-acting benzodiazepines | |
CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
JP2015520158A5 (hr) | ||
PE20150730A1 (es) | Compuestos de pirazolopirimidina | |
PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
RU2015116953A (ru) | Новые соединения | |
MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
PH12015500063A1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
HRP20180411T1 (hr) | Predlijekovi inhibitora aminokinazolinske kinaze | |
MX358172B (es) | Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson. | |
MX2019004941A (es) | Formulacion liposomal. | |
MX2012000954A (es) | Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. | |
NZ705994A (en) | Process for preparing pemetrexed di potassium and its hydrates | |
AR115019A2 (es) | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina | |
IN2013CH05870A (hr) | ||
CU20140140A7 (es) | 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 |